Advancing Pharmaceutical and Biotechnology Development through Global Collaboration

Challenges and Opportunities

September 29 and 30, 2017
DoubleTree by Hilton
Somerset Hotel and Conference Center
200 Atrium Drive
Somerset, NJ 08873, USA
Building upon last year’s record breaking success, this year’s SAPA Annual Conference will be expanded to one and half days – September 29th (Friday) afternoon and September 30th (Saturday). The theme for this year’s conference is “Advancing Pharmaceutical and Biotechnology Development through Global Collaboration: Challenges and Opportunities”. We have invited many distinguished speakers and professionals who will share their views and address key issues in the following areas:

- Breakthrough therapies for unmet medical needs
- Disruptive innovation for drug discovery and development
- Pharmaceutical investment
- Business development and licensing
- New advances in regulatory sciences
- Intellectual properties – recent high profile case studies
- Career planning, development, and advancement

Early-bird registration is now open
Preliminary Program

Plenary Sessions (Friday, September 29 and Saturday, September 30)
Session Moderators: Lei Tang, PhD and Jian Liu, PhD

Confirmed Speakers:

Ballroom West+Center
Friday afternoon, September 29: 1:00 pm -1:05 pm
• Debbie Hart, President and CEO, BioNJ 1:05 -1:30
• Theresa Mullin, PhD, Director, Office of Strategic Program, FDA/CDER and Chair of ICH management committee, FDA/CDER 1:30 – 2:00
• Mathias Hukkelhoven, PhD, SVP, Global Regulatory, Safety and Biometrics, BMS 2:00 -2:30
  Break 2:30 – 3:00
Saturday morning, September 30:
8:45 - 9:15
• David Ho, PhD, Professor, CEO of Aaron Diamond AIDS Research Center 9:15-9:45
• Christian Antoni, MD, PhD, VP, Head of Immunology Development, Sanofi 9:45-10:15
  Break 10:15 – 10:30
• Chris Chen, PhD, CEO, WuXi Biologics 10:30 -11:00
• Michael Foley, PhD, Director of Tri-I TDI and Sanders Innovation and Education Initiative 11:00 -11:30
• Yiwu He, PhD, MBA, CEO, BGI Groups USA 12:00

Keynote presentations at the plenary sessions will focus on advancing pharmaceutical and biotechnology development through global collaboration, challenges and opportunities on breakthrough and innovative therapies, capital investment, business development strategies, legal protection, and regulatory sciences. These distinguished leaders will share their experience and perspectives on global collaboration strategies and the impact on the innovative drug development and disruptive technology innovation.

Friday, September 29, afternoon sessions

Pharma Investment Forum
Session Moderators: Jin Wang, PhD and Xiaodong Chen, PhD

Confirmed speakers and panelists:
3:00 – 5:30 pm
• Hongbo Lu, PhD, MBA, Partner, Lilly Asian Ventures
• Feng Li, Founding Partner, Frees Fund
• Lawrence Tian, Founding Partner, Yuanming Capital
• Kimberly Nearing, Managing Director and Head of Life Sciences, Cedrus Investments
• Jin Wang, PhD, CEO, Manhattan Capital
Global collaboration with outsourcing — impact on pharma landscape

Session Moderators:  Jian Liu, PhD, and Lin Yan, PhD

3:00 – 5:30 pm

Confirmed Speakers:

- **Jeffrey Humphery, MD**, CMO and President, Kyowa Kirin Pharma 3:00 – 3:15
- **Francis Tse, PhD**, VP and CSO, New Jersey Site Head, WuXi AppTec LTD 3:15 – 3:30
- **Joseph Duffy, PhD**, Executive Director, External Discovery Chemistry, Merck 3:30 – 3:45
- **James Jianguo Yang, PhD**, President & CEO, Abpro China 3:45 – 4:00
- **Weikang Tao, PhD**, VP and CEO of R&D Center, Jiangsu Hengrui Medicine Co, LTD 4:00 – 4:15

Panelists: Panel discussion 4:15 – 5:30

- **John Yao, PhD**, CEO, TC Scientific
- **Deborah DiNoto, PhD**, Sr. Director, Business Management Operation, Sanofi

*In the book, the World is Flat: A Brief History of the Twenty-First Century, Thomas Friedman argues that globalization makes the world a level playing field, where all competitors have equal opportunities. Under such a competitive*
environment, traditional cost-saving outsourcing has evolved into a more advanced form of outsourcing, i.e., value-creating global collaboration, to drive new revenue, shorten time-to-market, lower the entry bar for new entrepreneur, and increase innovation. In this session, we are fortunate to have several CEOs and executives from small to large CROs, and managers in charge of external collaboration from big pharma to share their strategy — how to build sustainable competitive advantages for growth with global collaboration in current pharmaceutical landscape.

Saturday, September 30, afternoon parallel sessions
Two part of the afternoon is 1:00 – 3:00 pm and 3:30 – 5:00 pm
Coffee break 3:00 – 3:30 pm

Business Development Forum
1:00 – 3:00
Ballroom C
Session Moderators: Tong Zhang, PhD, Aming Zhang, PhD, and Frank Gan, PharmD

Confirmed Speakers:
- **Tong Zhang, PhD**, VP, Corporate BD, WuXi AppTec
- **Ji Li, PhD**, EVP, Business Development, BeiGene
- **Michael Keyoung, MD, PhD**, Managing Partner, Portola Capital Partners
- **Zhongda Zhang, PhD**, VP, Business Development, Pharmaron
- **Lily Zhou**, CEO, Fosun Pharma US
- **Hanzhong Li**, CFO, Ascentage

The importance of the business development and licensing (BD&L) function in the global biotech and biopharmaceutical industries has grown significantly over the past 20 years, as companies have sought to supplement their internal R&D with innovative products and technologies sourced through external licensing, joint ventures, acquisition of intellectual property rights, collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. These have required companies to employ BD&L executives to search, evaluate, negotiate and manage deals and alliances ranging from academic research institutes, to small biotechnology companies, and to the largest of the Big Pharma companies. The BD&L session at SAPA Annual Conference offers a unique opportunity to learn from industry experts on their valuable experience and latest industry trends. Don’t miss your chance to engage in discussions with speakers, hone your professional knowledge, and network with industry peers.

Scientific Session: Immuno-Oncology
Ballroom A
1:00 – 5:00
Session Moderators: Junfang Li, PhD, Jianda Yuan, MD, PhD, Yan Ni, PhD and Su-Feng Pu, MD, PhD

Confirmed Speakers:
- **Fener Chen, PhD**, Member of Chinese Academy of Science
- **Guanghui Hu, PhD**, CEO, Ademera
Immuno-oncology has revolutionized cancer treatment over the past decade and continues to yield new and exciting results. More and more new immunotherapies come into the clinics, from monoclonal antibody targeting the next generation of checkpoint inhibitors to oncolytic viral therapy, CAR-T cell therapy, and new cancer vaccines. The therapeutic approaches ranging from activating patients’ own immune system to attack cancer cells to neutralizing mechanism to regulate patient’s immune system, are increasingly implemented with much improved efficacy and unique safety profile which result in better quality of life for patients. In this exciting scientific session, the leading experts in the immune-oncology field will present the latest progress in cancer immunotherapy and novel clinical study designs, as well as recent innovations in cutting edge technology in pharmaceutical industry.

Career Development Session: The “Yin” and “Yang” of Career Development

1:00 – 5:00
Room 166

Session Moderators: John Sun, PhD, Ling Kang, PhD and Jiachang Gong, PhD

Confirmed Speakers:
- **Sara Bonstein, MBA**, EVP and CFO, Advasix
- **Kevin Huang, PhD**, Chief of Staff, WuXi Biologics
- **Pattie Drake**, VP Market Operations & Strategy Realization, Merck
- **Don Warkentin**, Leadership Trainer, Dale Carnegie
- **Lauren Supraner**, President, CAL Learning
- **Zhihong Ge, PhD**, AVP, Head of Global Development Quality, Merck
- **Weiyong Sun, MD, PhD, MBA**, Sr Dir, External Scientific Affairs, Global Business Development and Licensing, Daiichi Sankyo Group

In Chinese philosophy, Yin and Yang describe how seemingly opposite or contrary forces may actually be complementary, interconnected, and interdependent in the natural world, and how they may give rise to each other as they interrelate to one another. This concept can be readily applied to our journey on career planning, development, and advancement. Each of us have our own strength and weakness, also we need to consciously and effectively engage the external world. There are many examples of Yin and Yang balance or imbalance, and this session will dive deep and unveil the mask of career mysteries, ranging from different dimensions. Come to be intrigued and stimulated. Either way, this session will make you think differently about yourself on how to live a more productive and fulfilling life.
IP Session: IP Protection, Licensing, Enforcement, or Challenge as Business Strategies in Pharmaceutical and Biotech Industries
Room 158
1:00 – 5:00

Session Moderators: Wansheng Jerry Liu, PhD, JD and Hong Liu, PhD, JD

Confirmed Speakers:

- **Gerard Norton, PhD, JD**, Partner & Chair of IP Litigation, Fox Rothschild LLP
- **Lihua Zheng, PhD, JD**, Partner, Liu, Zheng, Chen & Hoffman LLP
- **Ken Zeidner, PhD, JD**, VP, Global IP Portfolio and Strategy, Amneal Pharmaceuticals
- **Jamie Hu, PhD, JD**, IP Counsel, Legal & Corporate Affairs, Novo Nordisk Inc.
- **Tatiana Litvin-Vechnyak, PhD**, Executive Director, Licensing & IP, Rutgers, the State University of New Jersey

*Intellectual Property is the lifeblood of pharmaceutical/biotech industries, often the only asset of a start-up or emerging company, and sometimes the very reason that a pharmaceutical/biotech company exists. Therefore, IP protection is crucial to a company’s business success, IP licensing is often the core of business transactions, and IP right enforcement and/or challenge has become an integral part of business strategies. As a result, high-profile patent litigations or IP right declarations are taking place in higher frequencies, often before any commercial value of the technology at issue has been proven or realized, and 8- or 9-digit patent licensing fees in hot therapeutic areas or multi-billion dollar verdicts in high-profile patent lawsuits have become norms rather than exceptions.*

This session will feature presentations and panel discussions by experienced in-house patent attorneys or IP managers as well as litigators and legal counsel from law firms on new development of pharmaceutical/biotech patent laws and trending legal strategies in IP protection, enforcement, licensing, and commercialization. Attendees will not only be able to gain valuable insight of various recent headline-grabbing patent lawsuits, but also be provided with opportunities to directly interact with the speakers to gain first-hand knowledge or information on any aspects of pharmaceutical patent laws.

The 2nd SAPA Annual Chinese CEO Forum – Stories Beyond the News
3:30 – 5:30
Hillsborough Room

Session Moderators: Charles Wang, PhD, Lei Tang, PhD and Jian Liu, PhD

Confirmed Speakers:

- **Li Chen, PhD**, President and CEO at Hua Medicine
- **Jinsong Cui, PhD**, President and CEO at InnoCare Pharma
- **Jiangbin John Hu, PhD**, Vice President, Huahai Pharmaceutical
- **Dahai Guo**, CEO at PuraCap
• Jim Huang, PhD, Founder & CEO at Ascendia Pharmaceuticals
• Weikang Tao, PhD, CEO at Jiangsu HengRui Medicine CO., LTD, R&D Centers
• Jianguo Yang, PhD, President and CEO at Abpro China
• Sean Xinghua Hu, PhD and MBA, SVP and Head of Consulting, Americas Pharmaceuticals and Diagnostics
• James S Yan, PhD, MD, DABT Executive Vice President Head of Early Development and Drug Safety, ZAI Lab
• Dan Zhang, PhD, MD, CEO, Fountain Medical Development Ltd

The SAPA Chinese CEO Forum is a unique platform for education, discussion and debate around current and future challenges and opportunities in the pharmaceutical industry.

Featured presentations will track the industry trends and provide projections and insights into future growth and development. It will also provide participants with strategic information needed as portfolios continue to advance and evolve. Topics will include healthcare policy and regulatory reform, economic models impacting the industry, current challenges in recruitment and talent development, successful recent M&A between U.S. and Chinese companies, and opportunities in unique and beneficial partnership structures. There will be a round-table discussion following the presentations for in-depth interaction with participants. You will get to hear true stories, opinions, and solutions from successful CEOs from both US and China; and have your questions answered by the industry leaders.

2017 SAPA Startup-Venture Summit – Where Innovation Meets Capital
Ballroom B
1:00 – 5:00

Session Moderators: Xiaodong Chen, PhD, Lei Tang, PhD, Jin Wang, PhD, and Le Zhan, PhD

Are you passionate about starting your own business or building your own company? Would you like to bring your unique science/technology into real-life applications? What is the most efficient way to “pitch” your business plans to investors? How to choose a startup company to work with, or to invest? What is the risk and benefit? If you are curious about any of these questions, don’t miss this brand new SAPA Startup-Venture Summit. There will be industry leaders in investment (VC/PE) and Business Development to join us as panelists and advisors. Ten early to middle stage biotech/life science startup companies will be selected to share their venture “pitch”.

This summit is designed to bridge startups and investments, to exchange innovative ideas and business plans, to analyze the pros and cons of a startup, to help you judge if you are ready to be your own boss, to inspire more forthcoming creative thoughts and executions. Come and join this exciting half-day event and be prepared, you can connect with investors, startups and potential partners through this high level networking opportunity.

Invited advisors and panelists:
• Angel Investors (Sangel Capital, BioClub)
• Venture Capitalists (Qiming Venture Partners, C-Bridge Capital, Yuanming Capital, Wuxi Ventures, Manhattan Capital, Frees Fund, Hangzhou Wise Wealth-Sharing Investment)
• Corporate Venture (Lilly Asian Venture, Hengrui, Luye Pharm, BGI, IDG, 3SBio)
• Technology transfer professionals in Top Universities (U Penn, Princeton, Yale, Columbia, Rutgers, John Hopkins, U of Maryland etc.)
• Entrepreneurs
• Incubators
• Legal counsel
• Researcher

Beyond RD  1:00 – 5:00
Princeton room

Shirley Ying and Xiaole Shen

RA  1:00 – 3:00
Bridgewater room

Xin Du, Li Wan, Veronica Chen
Sino-American Pharmaceutical Professionals Association
PO Box 282
Nanuet, NY 10954, USA
http://www.sapaweb.org
http://weibo.com/sapaweb
WeChat: